I publicerede, prospektive undersøgelser var peroral Prograf primært immunsuppressivum hos omkring 175 lungetransplanterede patienter, 475 pankreastransplanterede patienter og 630 intestinaltransplanterede patienter.
In prospective published studies oral Prograf was investigated as primary immunosuppressant in approximately 175 patients following lung, 475 patients following pancreas and 630 patients following intestinal transplantation.